Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies.
Saved in:
| Title: | Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies. |
|---|---|
| Authors: | Allen-Tejerina AM; Lister Hospital, Stevenage, UK., Giannakis P; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Ho Lai Yau T; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Hillyar CRT; Green Templeton College, University of Oxford, Oxford, UK., Rallis KS; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. hfy197@qmul.ac.uk.; Barts Cancer Institute, Queen Mary University of London, London, UK. hfy197@qmul.ac.uk. |
| Source: | Current oncology reports [Curr Oncol Rep] 2026 Mar 06; Vol. 28 (1). Date of Electronic Publication: 2026 Mar 06. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
